Targeting Cardiometabolic Risk Beyond Statins: A Systematic Review of Evolocumab in Statin-Intolerant Patients With Metabolic Syndrome. JOC 2025, 24 (3s), 441-448. https://doi.org/10.64149/J.Carcinog.24.3s.441-448.